Who Are the Core Customers in Lannett Company Company's Target Market?

Cencora, Cardinal Health, and McKesson are the main Lannett Company target customers because they distribute to most US pharmacies and hospitals; aggregate data show they drive about 85% – 90% of Lannett pharmaceutical customers' revenue, making pharmacy wholesalers and distributors critical buyers.

Large retail and independent pharmacies – CVS and Walgreens among them – plus Group Purchasing Organizations and hospital procurement departments form secondary customer segments; these channels determine formulary placement and volume purchases that affect Lannett Company customer segments and hospital procurement departments' sourcing.

Lannett mainly serves businesses and institutions – distributors, retail pharmacy chains, hospitals, and GPOs – while indirectly reaching patients via clinicians, insurance formularies, and pharmacy purchasing managers; the mix includes CDMO services for other pharmaceutical clients.

The most important segment is wholesale distributors (the Big Three), which by scale and revenue concentration control access to pharmacies and hospitals; loss of or shifts in purchasing by these wholesalers would materially affect Lannett's top-line and inventory turnover. Read more on company operations in How Lannett Company Company Works and Makes Money.

The Lannett Company target customers are primarily US hospital procurement departments, pharmacy wholesalers and distributors, and mail-order pharmacies because the US fills over 90% of prescriptions with generics; institutional channels handle high-volume chronic-care scripts.

Retail and independent pharmacies, long term care facilities, and retail pharmacy chains ordering Lannett products form secondary demand, plus government buyers (VA, public health) and pharmacy benefit managers influencing formularies.

Lannett pharmaceutical customers show strongest uptake in complex generics and hospital-supplied injectables where technical barriers limit competitors; revenue mix tilts toward high-volume generic contracts with pharmacy wholesalers and distributors.

Demand is growing fastest for affordable insulin products and respiratory treatments amid legislative pressure to lower drug prices and rising chronic disease prevalence; biosimilar adoption and complex generics expansion accelerate institutional and mail-order buys. See Mission, Vision, and Values of Lannett Company Company for related company context.

Lannett Company target customers expand as the company files ANDAs for low-competition generics and partners on biosimilars, enabling entry into hospital procurement departments, pharmacy wholesalers and distributors, retail and independent pharmacies, and institutional buyers without full clinical risk. Recent pipeline moves aim to add product listings to Growth Outlook of Lannett Company Company and increase customer reach in government and international markets.

Long-term contracts with major wholesalers and a domestic manufacturing footprint reduce supply risk for pharmacy purchasing managers, hospital pharmacy directors, and wholesale distributors who buy Lannett pharmaceuticals. Regulatory navigation expertise and on-time launches support pharmacy wholesalers and distributors and lower churn among retail pharmacy chains ordering Lannett products.

Repeat demand comes from formulary placements and long-term care facilities sourcing Lannett generics; insurance formularies listing Lannett pharmaceuticals and veterans affairs contracts increase reorder frequency. Ecosystem stickiness is driven by reliable supply to hospitals that purchase Lannett Company generic drugs and pharmacies stocking Lannett Company medications, supporting predictable volumes for distributors and independent pharmacists partnering with Lannett Company.

The key lever is timely biosimilar insulin launch and manufacturing optimization: if launched on schedule in 2025, market entry into clinicians prescribing Lannett Company generic drugs and pharmacy benefit managers negotiating with Lannett could lift volumes and margins. Management projects moderate growth for 2025/2026 with EBITDA margins expected to stabilize as the mix shifts to higher-barrier molecules; recent guidance implies margin improvement versus prior low-single-digit EBITDA in earlier years, contingent on execution and contract renewals with retail pharmacy chains ordering Lannett products.